Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
- Author(s)
- Stiegeler, N; Garsed, DW; Au-Yeung, G; Bowtell, DDL; Heinzelmann-Schwarz, V; Zwimpfer, TA;
- Journal Title
- Frontiers in Oncology
- Publication Type
- Review
- Abstract
- Approximately 50% of tubo-ovarian high-grade serous carcinomas (HGSCs) have functional homologous recombination-mediated (HR) DNA repair, so-called HR-proficient tumors, which are often associated with primary platinum resistance (relapse within six months after completion of first-line therapy), minimal benefit from poly(ADP-ribose) polymerase (PARP) inhibitors, and shorter survival. HR-proficient tumors comprise multiple molecular subtypes including cases with CCNE1 amplification, AKT2 amplification or CDK12 alteration, and are often characterized as "cold" tumors with fewer infiltrating lymphocytes and decreased expression of PD-1/PD-L1. Several new treatment approaches aim to manipulate these negative prognostic features and render HR-proficient tumors more susceptible to treatment. Alterations in multiple different molecules and pathways in the DNA damage response are driving new drug development to target HR-proficient cancer cells, such as inhibitors of the CDK or P13K/AKT pathways, as well as ATR inhibitors. Treatment combinations with chemotherapy or PARP inhibitors and agents targeting DNA replication stress have shown promising preclinical and clinical results. New approaches in immunotherapy are also being explored, including vaccines or antibody drug conjugates. Many approaches are still in the early stages of development and further clinical trials will determine their clinical relevance. There is a need to include HR-proficient tumors in ovarian cancer trials and to analyze them in a more targeted manner to provide further evidence for their specific therapy, as this will be crucial in improving the overall prognosis of HGSC and ovarian cancer in general.
- Publisher
- Frontiers
- Keywords
- CDK inhibitor; PARP inhibitor; PI3K inhibitor; antibody drug conjugate (ADC); homologous recombination proficiency; ovarian cancer; treatment resistance; vaccine
- Department(s)
- Laboratory Research
- Publisher's Version
- https://doi.org/10.3389/fonc.2024.1387281
- Open Access at Publisher's Site
https://doi.org/10.3389/fonc.2024.1387281- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-08-27 04:40:42
Last Modified: 2024-08-27 04:48:12